Abstract
The basis for the definition of a system as a synaptic system is its ability to induce EPSPs via ionotropic receptors/sodium channels or IPSPs via ionotropic receptors/chloride channels. Ionotropic receptors/sodium channels are present in the glutamatergic and acetylcholinergic system. The GABA and glycine systems have ionotropic receptors/chloride channels. The major synaptic systems of the mammalian brain are GABA- and glutamatergic systems. The physiological role of paracrine or diffuse neuromodulatory nonsynaptic systems is described by the example of dopaminergic and serotonergic systems. The mesolimbic and mesocortical dopaminergic systems form emotionally positive states. Nigrostriatal dopaminergic systems control behavior by modification of glutamate- and GABAergic ionotropic receptors of spiny neurons of neostriatum by a transduction signal. Description of the anatomical pathways of interaction of dopaminergic systems suggests that mesolimbic dopaminergic system induces purposeful emotionally motivated behavior via the nucleus accumbens, substantia nigra pars reticulata, and ventral pallidum. The physiological role of the serotonergic paracrine system is the formation of emotionally negative states. The antidepressant effect of tricyclic antidepressants depends on an initially negative state of animals, develops via interaction with the dopaminergic system, and, finally, is determined by the activation of the dopaminergic system of the brain.
Similar content being viewed by others
References
Nicoll, R.A., Malenka, R.C., and Kauer, J.A., Physiol. Rev., 1990, vol. 70, no. 2, pp. 513–565.
Sigma-RBI Handbook of Receptor Classification and Signal Transduction, 5th ed., K. Watling, Sigma-RBI, 2006.
Bazyan, A.S., Usp. Fiziol. Nauk, 2001, vol. 32, no. 3, pp. 3–22.
Shepard, G., Neirobiologiya. Vols 1, 2 (Neurobiology), Moscow: Mir, 1987.
Harley, C.W., Biol. Psychiat., 1987, vol. 11, pp. 419–458.
Raevskii, K.S, Sotnikova, T.D., and Gainetdinov, R.R., Usp. Fiziol. Nauk, 1996, vol. 27, no. 4, pp. 3–29.
Roth, R.H., Wolf, M.E., and Deutch, A.Y., Psychopharmacology: The Third Generation of Progress, Meltzer, H.Y., Ed., New York: Raven Press, 1987.
Roth, R.H., Wolf, M.E., and Deutch, A.Y., Psychopharmacology: The Fourth Generation of Progress, Bloom, F.E. and Kupfer, D.J., Eds., New York: Raven Press, 1995.
Bunin, M.A. and Wightman, R.M., Trends Neurosci., 1999, vol. 22, no. 9, pp. 377–382.
Hoyer, D., Clarke, D.E., Fozard, J.R., et al., Pharmacol. Rev., 1994, vol. 46, no. 2, pp. 157–203.
Iversen, L.L., Neurotransmis., 1994, vol. 10, no. 1, pp. 1–4.
Mayford, M., Abel T., Kandel E.R, Cur. Opin. Neurobiol., 1995, vol. 5, no. 1, pp. 141–148.
Deadwyler, S.A., Dunwiddie, T., and Lynch, G, Synapse, 1987, vol. 1, no. 1, pp. 90–95.
Abraham, W.C. and Otani, S., J. Physiol., 1988, vol. 407, no. 2, p. 50.
Otani, S. and Abraham, W.C., Neurosci. Lett., 1989, vol. 106, no. 1, pp. 175–180.
Otani, S., Marshall J., Tate W.P., et al, Neuroscience, 1989, vol. 28, no. 3, pp. 519–526.
Pauwels, P.J., Tocris Reviews, 2003, no. 25.
Val’dman, A.V. and Poshivalov, V.P., Farmakologicheskaya regulyatsiya vnutrividovogo povedeniya (Pharmacological Regulation of Intraspecific Behavior), Moscow: Meditsina, 1984.
Kruglikov, R.I., Neirokhimicheskie mekhanizmy obucheniya i pamyati (Neurochemical Mechanisms of Learning and Memory), Moscow: Nauka, 1981.
Greengard, P. and Allen, P.B., Neuron, 1999, vol. 23, no. 3, pp. 435–447.
Shabanov, P.D. and Lebedev, A.A., Fiziol. Zh. im. I.M. Sechenova, 1994, vol. 80, no. 11, pp. 19–25.
McGregor, I.S., Atrens, D.M., and Jackson, D.M., Psychopharmacol. Berl, 1992, vol. 106, no. 2, pp. 239–247.
Olds, M.E., Pharmacol. Biochem. Behav., 1995, vol. 50, no. 1, pp. 41–48.
Gratton, A. and Wise, R.A., J. Neurosci., 1994, vol. 14, no. 7, pp. 4130–4146.
Dackis, C.A. and Gold, M.S., Neurosci. Biobehav. Rev., 1985, vol. 9, pp. 469–477.
Hurd, Y.L., Weiss, F., Koob, G.F., et al., Brain Res., 1989, vol. 498, no. 2, pp. 199–203.
Hemby, S.R., Martin, T.J., and Co, C., et al., J. Pharm. Exp. Ther., 1995, vol. 273, no. 3, pp. 591–598.
Di Chiara, G., Behav. Brain Res., 2002, vol. 137, no. 1, pp. 75–114.
Gerrits, M.A.F.M., Petromilli, P., Westenberg, H.G.M., et al., Brain Res., 2002, vol. 924, no. 1, pp. 141–150.
Weiss, F., Markou, A., and Lorang, M.T., and Koob G.F., Brain Res., 1992, vol. 593, no. 3, pp. 314–318.
Acquas, A. and Di Chiara, G., J. Neurochem., 1992, vol. 58, no. 5, pp. 1620–1625.
Diana, M., Melis, M., Muntoni, A.L., and Gessa G.L., Proc. Nat. Acad. Sci. U.S.A., 1998, vol. 95, no. 17, pp. 10269–10273.
Rossetti, Z.L., Hmaidan, Y., and Gessa, G.L., Eur. J. Pharmacol., 1992, vol. 221, pp. 227–234.
Koob, G.F., Ann. New York Acad. Sci., 2000, vol. 909, no. 3, pp. 170–185.
Robertson, M.V., Leslie, C.A., and Bennett, J.P., Brain Res., 1991, vol. 538, pp. 337–339.
Weiss, F., Ciccocioppo, R., Parsons, L.H., et al., Ann. New York Acad. Sci., 2001, vol. 937, no. 1, pp. 1–26.
Koob, G.F., Ann. New York Acad. Sci., 1999, vol. 907, no. 10, pp. 445–460.
Koob, G.F. and Le Moal, M., Neuropsychopharmacol, 2001, vol. 24, pp. 97–129.
Caine, S.B. and Koob, G.F., J. Pharmacol. Exp. Ther., 1994, vol. 270, no. 1, pp. 209–218.
Caine, S.B., Negus, S.S., Mello, N.K., et al., J. Neurosci., 2002, vol. 22, no. 7, pp. 2977–2988.
Phillips, A.G., Pfaus, J.G., and Blaha, C.D., in The Mesolimbic Dopamine System: from Motivation to Action, Willner, P. and Scueel-Kruger, J., Eds., Willey, Chichester, 1991, pp. 199–224.
Wise, R.A., Brain Res., 1978, vol. 152, no. 2, pp. 215–247.
Wise, R.A., Life Sci., 1978, vol. 22, no. 7, pp. 535–542.
Gray, T. and Wise, R.A., Pharmacol. Biochem. Behav., 1980, vol. 6, pp. 931–935.
Blackburn, J.R., Phillips, A.G., Jakubovic, A., and Fibiger, H.C., Behav. Neurosci., 1989, vol. 103, no. 1, pp. 15–23.
Heffher, T.G., Luttinger, D., Hartman, J.A., and Seiden, L.S., Brain Res., 1981, vol. 214, no. 1, pp. 215–218.
Hernandez, L. and Hoebel, B.G., Life Sci., 1988, vol. 42, no. 18, pp. 1705–1712.
Joseph, M.H., Datla, K., and Young, A.M., Neurosci. Biobehav. Rev., 2003, vol. 27, no. 6, pp. 527–541.
Martel, P. and Fantino, M., Pharmacol. Biochem. Behav., 1996, vol. 55, no. 2, pp. 297–302.
Phillips, A.G., Coury, A., Fiorino, D., et al., Ann. New York Acad. Sci., 1992, vol. 654, pp. 199–206.
Kiyatkin, E.A. and Gratton, A., Brain Res., 1994, vol. 652, no. 2, pp. 225–234.
Yoshida, M., Yokoo, H., Mizoguchi, K., et al., Neurosci. Lett., 1992, vol. 139, no. 1, pp. 73–76.
Young, A.M., Joseph, M.H., and Gray, J.A., Neuroscience, 1992, vol. 48, no. 4, pp. 871–876.
Becker, J.B., Rudick, C.N., and Jenkins, W.J., J. Neurosci., 2001, vol. 21, no. 9, pp. 3236–3241.
Berridge, K.C., Robinson T.E., Brain Res. Rev., 1998, vol. 28, no. 3, pp. 309–369.
Di Chiara, G., Behav. Brain Res., 2002, vol. 137, no. 1, pp. 75–114.
Salamone, J.D., Behav. Brain Res., 1994, vol. 61, no. 2, pp. 117–133.
Salamone, J.D., Cousins, M.S., and Snyder, B.J., Neurosci. Biobehav. Rev., 1997, vol. 21, no. 3, pp. 341–359.
Blum, K., Braverman, E.R., Holder, J.M., et al., J. Psychoactive Drugs, 2000, vol. 32, pp. 1–112.
Ferrario, C.R., Gorny, G., Crombag, H.S., et al., Biol. Psychiatry, 2005, vol. 58, no. 9, pp. 751–759.
Valdomero, A., Isoardi, N.A., Orsingher, O.A., and Cuadra, G.R., Neuropharmacol., 2005, vol. 48, no. 4, pp. 538–546.
Gonzales, R.A., Job, M.O., and Doyon, W.M., Pharmacol. Ther., 2004, vol. 103, no. 2, pp. 121–146.
Cardinal, R.N., Winstanley, C.A., Robbins, T.W., and Everitt, B.J., Ann. New York Acad. Sci., 2004, vol. 102(1), pp. 33–50.
Fuchs, R.A., Evans, K.A., Parker, M.C., and See, R.E., Psychopharmacol. (Berl), 2004, vol. 176, no. 3, pp. 459–465.
McBride, W.J., Murphy, J.M., and Ikemoto, S., Behav. Brain Res., 1999, vol. 101, no. 2, pp. 129–152.
Ito, R., Robbins, T.W., and Everitt, B.J., Nat. Neurosci, 2004, vol. 7, no. 4, pp. 389–397.
Deransart, C., Riban, V., Le B.-T., et al., Neuroscience, 2000, vol. 100, pp. 335–344.
Buzsaki, G., Smith, A., Berger, S., et al., Neuroscience, 1990, vol. 36, pp. 1–14.
Getsova, V.M., Orlova, K.V., Folomkina, A.A., and Bazyan, A.S., Zh. Vyssh. Nervn. Deyat. im. I. P. Pavlova, 2003, vol. 53, no. 5, pp. 674–680.
Getsova, V.M., Orlova, N.V., Folomkina, A.A., et al., The WAG/Rij Model of Absence Epilepsy: The Nijmegan — Russian Federation Papers. Nijmegan Institute for Cognition and Information: The Netherlands, 2004, pp. 293–304.
Bazyan, A.S., Bikbulatova, L.S., Melnik, V.I., et al., The WAG/Rij Model of Absence Epilepsy. The Nijmegan — Russian Federation papers. Nijmegan Institute for Cognition and Information. The Netherlands, 2004, pp. 319–326.
Midzyanovskaya, K.S., Kuznetsova, T.D., Tuomisto, L., et al., Neirokhimiya, 2004, vol. 21, no. 4, pp. 254–260.
Biryukova, L.M., Midzyanovskaya, K.S., and Lensu, S., Neirokhimiya, 2006, vol. 23, no. 3, pp. 234–239.
Van Luitelaar, E.L.J.M. and Coenen, A.M.L., Neurosci. Lett., 1986, vol. 70, pp. 393–397.
Van Luitelaar, E.L.J.M. and Coenen, A.M.L., The WAG/Rij Model of Absence Epilepsy: Ten Years of Research. A Computation of Papers. Nijmegen University Press. Nijmegan. The Netherlands, 1997.
Midzianovskaya, I.S., Kuznetsova, G.D., Coenen, A.M.L., et al., Brain Res., 2001, vol. 911, pp. 62–70.
Meeren, H.K.M., Pijn, J.P.M., van Luitelaar, E.L.J.M., et al., J. Neurosci., 2002, vol. 22, pp. 1480–1495.
Inoue, M., Duysens, J., Vossen, J.M.H., and Coenen, A.M.L., Brain. Res, 1993, vol. 612, pp. 35–40.
Seidenbecher, T., Staak, R., and Pape, H.C., Eur. J. Neurosci., 1998, vol. 10, pp. 1103–1112.
De Bruin, N.M.W.J., Luijtelaar, E.L.J.M., Jansen, S.J., et al., Neurosci. Res., 2000, vol. 38, pp. 165–173.
Warter, J.-M., Verognes, M., Depaulis, A., et al., Neuropharmacol., 1988, vol. 27, pp. 269–274.
Lester, J., Fink S., Aronin N., DiFiglia M, Brain Res., 1993, vol. 621, pp. 106–110.
Tamminga, C.A., and Carlsson, A., Curr. Drug Targets CNS Neurol. Disord., 2002, vol. 1, pp. 141–147.
Pothos, E.N., Behav. Brain Res., 2002, vol. 130, pp. 203–207.
Bazyan, A.S., Getsova, V.M., and Orlova, N.V., Neuroscience, 2000, vol. 99, pp. 279–288.
Sarkisova, K.Yu., Midzianovskaia, I.S., and Kulikov, M.A., Behav. Brain Res., 2003, vol. 144, pp. 211–226.
Sarkisova, Yu. and Kulikov, M.A., Behav. Brain Res., 2006, vol. 166, pp. 9–18.
Tran, A.H., Tamura, R., Uwano, T., et al., Proc. Natl. Acad. Sci. USA, 2005, vol. 102, no. 6, pp. 2117–2122.
Bari, A.A. and Pierce, R.C., Neuroscience, 2005, vol. 135, no. 3, pp. 959–968.
Olsen, C.M. and Duvauchelle, C.L., Brain Res., 2006, vol. 1075, no. 1, pp. 229–235.
Sorg, B.A., Li, K., Wu, W., and Bailie, T.M., Neuroscience, 2004, vol. 127, no. 1, pp. 187–196.
Tran, A.H., Tamura, R., Uwano, T., et al., Proc. Natl. Acad. Sci. USA, 2005, vol. 102, no. 6, pp. 2117–2122.
Bari, A.A. and Pierce, R.C., Neuroscience, 2005, vol. 135, no. 3, pp. 959–968.
Choi, K.H., Clements, R.L., and Greenshaw, A.J., Behav. Brain Res., 2005, vol. 158, no. 1, pp. 79–88.
Xi, Z.X., Gilbert, J.G., Pak, A.C., et al., Eur. J. Neurosci, 2005, vol. 21, no. 12, pp. 3427–3438.
Ichimaru, Y., Egawa, T., and Sawa, A., Jpn. J. Pharmacol, 1995, vol. 68, no. 1, pp. 65–70.
Kennett, G.A., Pittaway, K., and Blackburn, T.P., Psychopharmacol. Berl, 1994, vol. 114, no. 1, pp. 90–96.
Kennett, G.A., Bailey, F., Piper, D.C., and Blackburn, T.P., Psychopharmacol. Berl, 1995, vol. 118, no. 2, pp. 178–182.
Molewijk, H.E., Van Der Poel, A.M., and Olivier, B., Psychopharmacol. Berl, 1995, vol. 121, no. 1, pp. 81–90.
Shepherd, J.K., Grewal, S.S., Fletcher, A., et al., Psychopharmacol. Berl, 1994, vol. 116, no. 1, pp. 56–64.
Ferraro, L., Fuxe K., Agnati, L., et al. Synapse, 2005, vol. 55, no. 4, pp. 230–341.
Keck, M.E., Sartori, S.B., Welt, T., et al., J. Neurochem., 2005, vol. 92, no. 5, pp. 1170–1179.
Quintin, P. and Thomas, P., Encephale, 2004, vol. 30, no. 6, pp. 583–589.
Winstanley, C.A., Dalley, J.W., Theobald, D.E., and Robbins, T.W., Psychopharmacol. Berl., 2003, vol. 170, no. 3, pp. 320–331.
Winstanley, C.A., Theobald, D.E., Dalley, J.W., and Robbins, T.W., Neuropsychopharmacol, 2005, vol. 30, no. 4, pp. 669–682.
Brunner, H.G., Nelen, M., Drakefield, X.O., et al., Science, 1993, vol. 262, pp. 578–580.
Cases, O., Self, I., Grimsby, J., and Gaspar, P., Science, 1995, vol. 268, pp. 1763–1766.
De Maeyer, E., Self, I., Cases, O., and Gaspar, P., in: Violence: From Biology to Society, Grisolia, J.S., Ed.,. Elsevier Science: Berlin, 1997, pp. 71–78.
Felton, T.M., Kang T.B., Hjorth S., Auerbach S.B, Naunyn-Schmiedeberg’s Arch. Pharmacol., 2003, vol. 367, no. 3, pp. 297–305.
Gur, E. and Lifschytz, T., Lerer B., Newman M.E, Eur. J. Pharmacol., 2002, vol. 457, no. 1, pp. 37–43.
Rosel, P., Arranz, B., Urretavizcaya, M., et al., Psychiatry Res., 2002, vol. 111, no. 2, pp. 105–115.
Yoshitake, T., Fujino, K., Kehr, J., et al., Anal. Biochem., 2003, vol. 312, no. 2, pp. 125–133.
Yoshitake, T., Reenila, L., Ogren, S.O., et al., Neurosci. Lett., 2003, vol. 339, no. 3, pp. 239–242.
Rickels, K. and Rynn, M., J. Clin. Psychiatry, 2002, vol. 63,suppl. 14, pp. 9–16.
Sanchez, C., Eur. J. Pharmacol., 2003, vol. 463, nos. 1–3, pp. 133–143.
Tottori, K., Miwa, T., Uwahodo, Y., et al., Neuropharmacol., 2001, vol. 41, no. 8, pp. 976–988.
Folomkina, A.A., Orlova, K.V., and Bazyan, A.S., Zh. Vyssh. Nervn. Deyat. im. I. P. Pavlova, 2004, vol. 54, no. 5, pp. 685–690.
Orlova, N.V., Folomkina, A.A., Koshtoyants, O.Kh., and Bazyan, A.S., Zh. Vyssh. Nervn. Deyat. im. I.P. Pavlova, 2005, vol. 55, no. 1, pp. 65–70.
Dekeyne, A., Gobert, A., Auclair, A., et al., Psychopharmacol. Berl., 2002, vol. 162, no. 2, pp. 156–167.
Evenden, J.L., Psychopharmacol. Berl., 1998, vol. 138, no. 3, pp. 283–294.
Evenden, J.L., Psychopharmacol Berl., 1998, vol. 138, no. 3, pp. 295–304.
Evenden, J., Psychopharmacol. Berl., 1999, vol. 143, no. 2, pp. 111–122.
Bobula, B., Tokarski, K., and Hess, G., Pol. J. Pharmacol., 2001, vol. 53, no. 6, pp. 635–639.
De La Garza, R., Jentsch, J.D., Verrico, C.D., and Roth, R.H., Brain Res., 2002, vol. 958, no. 1, pp. 20–27.
Wood, M.D., Thomas, D.R., and Watson, J.M., Expert. Opin. Investig. Drugs, 2002, vol. 11, no. 4, pp. 457–467.
Matrisciano, F., Storto, M., Ngomba, R.T., et al., Neuropharmacol., 2002, vol. 42, no. 8, pp. 1008–1015.
Varona, A., Gil, J., Saracibar, G., et al., Arzneimittelforschung, 2003, vol. 53, no. 1, pp. 21–25.
Chardenot, P., Roubert, C., Galiegue, S., et al., Mol. Pharmacol., 2002, vol. 62, no. 6, pp. 1314–1320.
Nicholson, G.M., Blanche, T., Mansfield, K., and Tran, Y., Eur. J. Pharmacol., 2002, vol. 452, no. 1, pp. 35–48.
Yang, Y.C. and Kuo, C.C., Mol. Pharmacol., 2002, vol. 62, no. 5, pp. 1228–1237.
Mochizuki, D., Hokonohara, T., Kawasaki, K., and Miki, N., J. Psychopharmacol, 2002, vol. 16, no. 3, pp. 253–260.
Baamonde, A., Dauge, V., Ruiz-Gayo, M., et al., Eur. J. Pharmacol., 1992, vol. 216, no. 2, pp. 157–166.
D’Aquila, P.S., Peana, A.T., Panin, F., et al., Eur. J. Pharmacol., 2003, vol. 458, no. 1, pp. 129–134.
De Montis M.G., Gambarana C., and Meloni D. Eur. J. Pharmacol., 1993, vol. 249, no. 2, pp. 179–183.
Gambarana, C., Ghiglieri, O., Tagliamonte, A., et al., Pharmacol. Biochem. Behav., 1995, vol. 50, no. 2, pp. 147–151.
Muscat, R., Sampson, D., and Willner, P. Biol. Psychiatry, 1990, vol. 28, pp. 223–230.
Ossowsk, G., Nowak G., Klenk-Majewskal B., et al., Pol. J. Pharmacol., 2002, vol. 54, no. 2, pp. 89–93.
Rogoz, Z. and Skuza, G., Pol. J. Pharmacol., 2001, vol. 53, no. 6, pp. 571–576.
Takamori, K., Yoshida, S., and Okuyama, S. Life Sci., 2001, vol. 69, no. 16, pp. 1919–1926.
Folomkina, A.A., Orlova, N.V., and Bazyan, A.S., Doclady Akad. Nauk, 2007, vol. 413, no. 5, pp. 703–706.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © A.S. Bazyan, O.L. Segal, 2009, published in Neirokhimiya, 2009, Vol. 26, No. 2, pp. 93–103.
Rights and permissions
About this article
Cite this article
Bazyan, A.S., Segal, O.L. Synaptic and paracrine nonsynaptic systems of the mammalian brain. Neurochem. J. 3, 77–86 (2009). https://doi.org/10.1134/S1819712409020019
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1819712409020019